Complete Protection of Mice against a Lethal Dose Challenge of Western Equine Encephalitis Virus after Immunization with an Adenovirus-Vectored Vaccine


  1. Wu, J.Q.H.
  2. Barabé, N.D.
  3. Chau, D.
  4. Wong, C.
  5. Rayner, G.R.
  6. Hu, W.-G.
  7. Nagata, L.P.
Corporate Authors
Defence R&D Canada - Suffield, Ralston ALTA (CAN)
Western equine encephalitis virus (WEEV) is an important pathogen for both humans and equines. The virus is also listed as a bioterrorism agent due to its ability for aerosol transmission with high mortality, No commercials vaccines or antiviral drugs are available for the prevention and treatment of' WEEV infection in humans. In this paper, we constructed a recombinant WEEV vaccine, designated as Ad5-WEEV, using a replication defective, human adenovirus serotype 5 (HAd5) as a delivery vector Ad5-WEEV contains the E3-E2-6K-E1 structural protein gene of the 71V-1658 strain of WEEV and the El and E2 proteins were synthesized in cells inoculated with Ad5-WEEV. After intramuscular immunization of mice with two doses of Ad5-WEEV, neutralizing antibodies against WEEV were generated and the mice were completely protected from a lethal dose challenge of 71 V-1658. In addition, we showed that passive transfer of serum from the Ad5-WEEV-immunized mice could partially control WEEV infection. These results demonstrate that HAd5 vectors are promising for WEEV vaccine development.
WEEV (Western Equine Encephalitis Virus);Gene therapy
Report Number
DRDC-SUFFIELD-SL-2006-115 — Scientific Literature
Date of publication
21 Feb 2007
Number of Pages
Reprinted from
Vaccine, vol 25, 2007, p 4368-4375
Hardcopy;Document Image stored on Optical Disk

Permanent link

Document 1 of 1

Date modified: